Breaking News

Catalent, Umn Pharma in Biosimilar Pact

December 13, 2012

Will use GPEx technology to produce cell lines

Catalent Pharma Solutions has signed an agreement with UMN Pharma, Inc. to provide a broad range of biosimilar cell lines using its GPEx technology. UMN and its subsidiary Unigen, will produce a number of biosimilars using Catalent’s GPEx cell lines. UMN will build an alliance of pharmaceutical companies for product development including clinical trials, marketing and sales. UMN plans to begin multiple biosimilar projects through alliances for the Asian market.
 
“There are great synergies between UMN Pharma and Catalent in terms of technologies, business structure, speed and culture,” said Masahiro Michishita, executive chairman of UMN Pharma. “Harnessing Catalent’s broad biologics development and cell construction expertise gives UMN Pharma a unique platform to grow our biosimilars business globally.”
 
Barry Littlejohns, Catalent’s business unit president, said, “This agreement will allow Catalent to continue to grow its biologics development and manufacturing interests of multiple biosimilars and NBEs, particularly in the Asian market. UMN Pharma’s ambitious expansion plans reflect Catalent’s strategy for growth in what we consider to be a key market.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.